54 completed, 4 withdrawn, 2 active not recruiting, 2 terminated. 23 Phase 2, 13 Phase 3, 8 Not applicable, 8 Phase 4, 7 Phase 1.
Follow ORA, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye 0.25% RCI001 Ophthalmic Solution, Placebo Ophthalmic Solution (vehicle) - Dry Eye Disease (DED) | Phase 2 | Not yet recruiting | ORA, Inc. | 200 | 2025-08-01 | 2025-07-16 |
| AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal Cataract Surgery - Cataract Senile | Not applicable | Completed | Carl Zeiss Meditec, Inc. | 284 | 2024-07-12 | 2026-08-13 |
| A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) AZR-MD-001, Vehicle - Dry Eye Disease | Phase 3 | Unknown | Azura Ophthalmics | 500 | 2024-05-28 | 2024-09-27 |
| Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM) 2C-QD, Sham 2C-QD - Retinitis Pigmentosa | Not applicable | Withdrawn | 2C Tech Corp | 2024-03-20 | 2025-06-12 | |
| Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED) ST-100 (vezocolmitide), Vehicle - Dry Eye Disease | Phase 3 | Unknown | ORA, Inc. | 175 | 2023-12-29 | 2024-01-18 |
| Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease licaminlimab, vehicle of OCS-02, Artificial tears - Dry Eye Disease | Phase 2 | Completed | Oculis | 122 | 2023-11-29 | 2025-07-02 |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration NG101 AAV gene therapy - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Elisigen, Inc. | 20 | 2023-09-08 | 2026-09-10 |
| Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia Aceclidine + Brimonidine, Aceclidine - Eye Diseases, Presbyopia | Phase 1 | Completed | LENZ Therapeutics, Inc | 30 | 2023-07-06 | 2023-10-16 |
| The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease OK-101, Placebo - Dry Eye Disease | Phase 2 | Completed | Okyo Pharma Ltd | 240 | 2023-04-28 | 2024-02-09 |
| A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye SI-614, Placebo - Dry Eye Disease | Phase 3 | Completed | Seikagaku Corporation | 232 | 2022-07-28 | 2026-01-16 |
| Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD smaller incision, new generation implantable miniature telescope (SING-IMT) - Age-Related Macular Degeneration, Geographic Atrophy | Not applicable | Recruiting | VisionCare, Inc. | 125 | 2022-06-16 | 2024-12-03 |
| A Study of AG-80308 in Dry Eye Patients AG-80308 - Dry Eye Disease | Phase 1 | Completed | Allgenesis Biotherapeutics Inc. | 84 | 2022-06-13 | 2022-11-29 |
| Study of ST-100 as Treatment for Dry Eye Disease ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye Disease | Phase 2 | Completed | Stuart Therapeutics, Inc. | 160 | 2021-05-17 | 2024-03-13 |
| Study of OT-101 in Treating Myopia OT-101 Ophthalmic Solution, Vehicle - Myopia, Progressive | Phase 3 | Active not recruiting | Ocumension (Hong Kong) Limited | 678 | 2021-04-01 | 2023-08-08 |
| Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye PL9643 Ophthalmic Solution, Placebo Ophthalmic Solution - Dry Eye Disease | Phase 2 | Completed | ORA, Inc. | 160 | 2020-02-14 | 2020-11-13 |
| Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 610 | 2019-12-20 | 2022-01-19 |
| Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT. Pro-ocular™ topical gel, Placebo topical gel - Chronic Ocular Graft-versus-host Disease | Phase 2 | Completed | Glia, LLC | 33 | 2019-10-17 | 2025-05-06 |
| A Prospective Clinical Study to Evaluate the Repeatability of the Visibly Vision Test Visibly Vision Test - Myopia, Astigmatism | Not applicable | Completed | Visibly | 25 | 2019-03-04 | 2025-02-06 |
| Study of SkQ1 as Treatment for Dry-eye Syndrome Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle) - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 452 | 2018-12-06 | 2022-01-19 |
| A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease AXR-159, Vehicle - Dry Eye | Phase 2 | Completed | AxeroVision, Inc. | 102 | 2018-06-26 | 2023-10-13 |
Showing 20 of 66. Sign in to see all of them.
Dry Eye Syndromes (25) · Conjunctivitis, Allergic (14) · Rhinitis, Allergic (6) · Macular Degeneration (5) · Keratoconjunctivitis (4) · Keratoconjunctivitis Sicca (4) · Eye Diseases (3) · Hyperemia (3) · Cataract (2) · Food Hypersensitivity (2) · Astigmatism (1) · Choroidal Neovascularization (1) · Corneal Diseases (1) · Eye Infections (1) · Geographic Atrophy (1)
Brimonidine Tartrate (4) · Dexamethasone (4) · Fluorescein (2) · Lubricant Eye Drops (2) · Methylprednisolone (2) · Visomitin (2) · Cataract Extraction (1) · Cetirizine (1) · Fluticasone (1) · Gels (1) · Hypromellose Derivatives (1) · Ketorolac (1) · Ketotifen (1) · Loteprednol Etabonate (1) · Olopatadine Hydrochloride (1)
United States (55) · Canada (1)
Gail Torkildsen, MD (5) · Tarek Shazly, MD (3) · H. Jerome Crampton, MD (2) · Heleen DeCory (2) · Henry J. Crampton, MD (2) · Keith Lane (2) · Lawrence T Friedhoff, MD, PhD (2) · Paul Gomes, MS (2) · Charles Bosworth, PhD (1) · Christopher D Riemann, MD (1) · Emily Schoemmell (1) · Eugene McLaurin, MD (1) · Eugene Protzko, MD (1) · G Torkildsen, MD (1) · Gail L Torkildsen, MD (1)
PMID 22435675, PMID 25686388, PMID 26689380, PMID 26733410, PMID 26890669, PMID 28933582, PMID 28956287, PMID 29461408, PMID 30248890, PMID 30881050, PMID 33882269, PMID 33942724, PMID 36811846, PMID 37260844, PMID 37677000